IP Verse

Nep Inhibitors For Treating Diseases Characterized By Atrial Enlargement Or Remodeling - EP2887961

The patent EP2887961 was granted to Novartis on Apr 28, 2021. The application was originally filed on Aug 22, 2013 under application number EP13750725A. The patent is currently recorded with a legal status of "Revoked".

EP2887961

NOVARTIS
Application Number
EP13750725A
Filing Date
Aug 22, 2013
Status
Revoked
Dec 9, 2022
Grant Date
Apr 28, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (6)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ALGEMEEN OCTROOI EN MERKENBUREAUJan 28, 2022ALGEMEEN OCTROOI EN MERKENBUREAUADMISSIBLE
GENERICS UKJan 28, 2022ELKINGTON AND FIFEADMISSIBLE
STADA ARZNEIMITTELJan 28, 2022KERNEBECKADMISSIBLE
TEVA PHARMACEUTICALSJan 27, 2022D YOUNGADMISSIBLE
WUESTHOFF & WUESTHOFF PATENTANWALTE PARTG MBBJan 27, 2022SONNENHAUSERADMISSIBLE
ALFRED E TIEFENBACHERJan 26, 2022HAMM & WITTKOPPADMISSIBLE

Patent Citations (42) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0034285
DESCRIPTIONEP0034391
DESCRIPTIONEP0036136
DESCRIPTIONEP0059044
DESCRIPTIONEP0063662
DESCRIPTIONEP0443983
DESCRIPTIONGB2218983
DESCRIPTIONJPH06234754
DESCRIPTIONJPH07157459
DESCRIPTIONUS4610816
DESCRIPTIONUS4722810
DESCRIPTIONUS4740499
DESCRIPTIONUS4749688
DESCRIPTIONUS4929641
DESCRIPTIONUS5217996
DESCRIPTIONUS5223516
DESCRIPTIONUS5250522
DESCRIPTIONUS5273990
DESCRIPTIONUS5294632
DESCRIPTIONUS5399578
DESCRIPTIONWO03059345
DESCRIPTIONWO2007056546
DESCRIPTIONWO2009061713
DESCRIPTIONWO9009374
DESCRIPTIONWO9214706
DESCRIPTIONWO9309101
DESCRIPTIONWO9310773
DESCRIPTIONWO9415908
DESCRIPTIONZA8400670
INTERNATIONAL-SEARCH-REPORTUS5217996
INTERNATIONAL-SEARCH-REPORTWO03059345
INTERNATIONAL-SEARCH-REPORTWO2006086456
INTERNATIONAL-SEARCH-REPORTWO2007056546
INTERNATIONAL-SEARCH-REPORTWO2009061713
INTERNATIONAL-SEARCH-REPORTWO2012027237
OPPOSITIONUS5217996
OPPOSITIONWO03059345
OPPOSITIONWO2006086456
OPPOSITIONWO2007056546
OPPOSITIONWO2009061713
OPPOSITIONWO2012027237
OPPOSITIONWO2014029848

Non-Patent Literature (NPL) Citations (36) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Anonymous, "LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction", ClinicalTrials - History of change NCT00887588, (20110719), URL: https://www.clinicaltrials.gov/ct2/history/NCT00887588?V_9=View, XP055889074-
OPPOSITION- Anonymous, "LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction", History of Changes for Study: NCT00887588, (20111119), History of Changes for Study: NCT00887588, URL: https://clinicaltrials.gov/ct2/history/NCT00887588?V_9=View#StudyPageTop, (20220208), XP055889074-
OPPOSITION- CUCULI, FLORIM et al., "Combined neutral endopeptidase inhibitors", Expert Opinion on Investigational Drugs, (20110000), vol. 20, no. 4, XP055780113-
OPPOSITION- FDA, "Diovan (valsartan) Tablets", Highlights of Prescribing Information, (20110401), XP055889086-
OPPOSITION- FDA, "Entresto® (sacubitril/valsartan) for Chronic Heart Failure and Preserved Ejection Fraction", CARDIOVASCULAR AND RENAL DRUGS ADVISORY COMMITTEE BRIEFING DOCUMENT, (20201215), pages 1 - 87, XP055888793-
OPPOSITION- Frank Antwerpes, Ibrahim Güler, Christoph Wirth, "Ejektionsfraktion", DocCheck Flexikon, (20201201), DocCheck Flexikon, URL: https://flexikon.doccheck.com/de/Ejektionsfraktion?utm_source=www.doccheck.flexikon&utm_medium=web&utm_campaign=DC%2BSearch, (20220214), XP055891056-
OPPOSITION- Gerd Hasenfuß, "Diastolische Herzschwäche ist weit verbreitet", Deutsche Herzstiftung, (20220101), Deutsche Herzstiftung, URL: https://www.herzstiftung.de/infos-zu-herzerkrankungen/herzinsuffizienz/linksherzinsuffizienz/diastolische-herzinsuffizienz#:~:text=Jahrelanger%20Bluthochdruck%20und%20hohes%20Alter%20sind%20die%20gr%C3%B6%C3%9Ften%20Risikofaktoren.&text=Bei%20der%20diastolischen%20Herzschw%C3%A4che%20(diastolische,Elastizit%C3%A4t%2C%20um%20gen%C3%BCgend%20Blut%20aufzunehmen., (20220214), XP055891050-
OPPOSITION- John J.V. Mcmurray, Stamatis Adamopoulos, Et Al, "ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012", European Heart Journal, (20120701), vol. 33, no. 14, pages 1787 - 1847, XP055891040-
OPPOSITION- Kobalava Z., Kovskayay., Meray I., Glovenko A., Moiseev V., Albrecht D, Feng A., Chandra P. Jordaan P., "P4409 Clinic blood pressure in stables heart failure patients treated with the dual-acting neprilysin and angiotensin receptor inhibitor LCZ696", European Heart Journal, (20110101), page 788, XP055891073-
OPPOSITION- "LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction", History of Changes for Study: NCT00887588, (20111119), URL: https://clinicaltrials.gov/ct2/history/NCT00887588?V_9=View#StudyPageTop, (20220208), XP055889074-
OPPOSITION- Novartis, "Annual Report 2010", Novartis AG, (20101231), URL: https://www.novartis.com/sites/novartis_com/files/novartis-annual-report-2010-en.pdf, XP055891063-
OPPOSITION- Shelley Wood, "What's Going to be Hot at the ESC 2012 Congress", Medscape, (20120821), pages 1 - 2, URL: https://www.medscape.com/viewarticle/769459, XP055891035-
OPPOSITION- Z. Kobalava, Averkov O. , Meray I. , Alexandriya L. , Moiseev V. , Albrecht D. , Feng A. , Chandra P. , Jordaan P.J., "Natriuretic peptide inhibition in the presence of angiotensin receptor blockade following short-term treatment with LCZ696 in heart failure patients: Effect on ANP, BNP, NT-proBNP and cGMP", European Heart Journal, (20110101), vol. 32, no. P4396, P4409, pages 784; - 785; 788, XP055751748-
OPPOSITION- ARONSON, KRUM, "Novel therapies in acute and chronic heart failure", Pharmacology & Therapeutics, (20120000), vol. 135, doi:10.1016/j.pharmthera.2012.03.002, pages 1 - 17, XP028503167
OPPOSITION- DORON ARONSON et al., "Novel therapies in acute and chronic heart failure", Pharmacology & Therapeutics, (20120000), vol. 135, doi:10.1016/j.pharmthera.2012.03.002, pages 1 - 17, XP028503167
OPPOSITION- Doron Aronson; Henry Krum;, "Novel therapies in acute and chronic heart failure", Pharmacology & Therapeutics, GB , (20120701), vol. 135, no. 1, doi:10.1016/j.pharmthera.2012.03.002, ISSN 0163-7258, pages 1 - 17, XP028503167
OPPOSITION- L.M. RUILOPE et al., "Blood pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised. Double-blind, placebo- controlled, active comparator study", The Lancet, vol. 375, doi:10.1016/S0140-6736(09)61966-8, (20100316), pages 1255 - 66, XP027490781
OPPOSITION- Luis Miguel Ruilope, Andrej Dukat, Michael Böhm, Yves Lacourcière, Jianjian Gong, Martin P Lefkowitz,, "Blood-pressure reduction with LCZ696, a novel dueal-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study", The Lancet, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20100410), vol. 375, no. 9722, doi:10.1016/S0140-6736(09)61966-8, ISSN 0140-6736, pages 1255 - 1266, XP002676955
OPPOSITION- RUILOPE et al., "Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo- controlled, active comparator study", The Lancet, (20100000), vol. 375, doi:10.1016/S0140-6736(09)61966-8, pages 1255 - 1266, XP027490781
OPPOSITION- Ruilope, L.M. ; Dukat, A. ; Bohm, M. ; Lacourciere, Y. ; Gong, J. ; Lefkowitz, M.P., "Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study", The Lancet, AMSTERDAM, NL , (20100410), vol. 375, no. 9722, doi:10.1016/S0140-6736(09)61966-8, ISSN 0140-6736, pages 1255 - 1266, XP027490781
OPPOSITION- RUILOPE, LUIS MIGUEL et al., "Blood-pressure reduction with LCZ696, a novel dual- acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double- blind, placebo-controlled, active comparator study", Lancet, (20100000), vol. 375, no. 9722, doi:10.1016/S0140-6736(09)61966-8, XP002676955
OPPOSITION- SCOTT D SOLOMON et al., "The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double blind randomised trial", The Lancet, vol. 380, doi:10.1016/S0140-6736(12)61227-6, (20120826), pages 1387 - 1395, XP055083562
OPPOSITION- Scott D Solomon, Michael Zile, Burkert Pieske, Adriaan Voors, Amil Shah, Elisabeth Kraigher-Krainer, Victor Shi, Toni Bransford, Madoka Takeuchi, Jianjian Gong, Martin Lefkowitz, Milton Packer, John Jv Mcmurray, "The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial", The Lancet, (20121001), vol. 380, no. 9851, doi:10.1016/S0140-6736(12)61227-6, ISSN 01406736, pages 1387 - 1395, XP055083562
OPPOSITION- Scott D Solomon, Michael Zile, Burkert Pieske, Adriaan Voors, Amil Shah, Elisabeth Kraigher-Krainer, Victor Shi, Toni Bransford, Madoka Takeuchi, Jianjian Gong, Martin Lefkowitz, Milton Packer, John Jv Mcmurray, "The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial", The Lancet, ¬J.B. Flint|, (20121001), vol. 380, no. 9851, doi:10.1016/S0140-6736(12)61227-6, ISSN 01406736, pages 1387 - 1395, XP055083562
OPPOSITION- Paulis Ludovit, Steckelings Ulrike M., Unger Thomas, "Key advances in antihypertensive treatment", Nature Reviews Cardiology, Nature Publishing Group, GB, GB , (20120501), vol. 9, no. 5, doi:10.1038/nrcardio.2012.33, ISSN 1759-5002, pages 276 - 285, XP055891032
OPPOSITION- Solomon Scott D., Mcmurray John J.V., Anand Inder S., Ge Junbo, Lam Carolyn S.P., Maggioni Aldo P., Martinez Felipe, Packer Milton, Pfeffer Marc A., Pieske Burkert, Redfield Margaret M., Rouleau Jean L., Van Veldhuisen Dirk J., Zannad Faiez, Zile Michael R., Desai Akshay S., Claggett Brian, Jhund Pardeep S., Boytsov Sergey A., Comin-Colet Josep, Cleland John, Düngen Hans-Dirk, Goncalvesova Eva, Katova Tzvetana, Kerr Saraiva Jose F., Lelonek Małgorzata, Merkely Bela, Senni Michele, Shah Sanjiv J., Zhou Jingmin, Rizkala Adel R., Gong Jianjian, Shi Victor C., Lefkowitz Martin P., "Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction", The New England journal of medicine, Massachusetts Medical Society, US, US , (20191024), vol. 381, no. 17, doi:10.1056/NEJMoa1908655, ISSN 0028-4793, pages 1609 - 1620, XP055891041
OPPOSITION- PONIKOWSKI et al., "2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure", European Heart Journal, (20160000), vol. 37, doi:10.1093/eurheartj/ehw128, pages 2129 - 2200, XP055360432
OPPOSITION- John J. V. Mcmurray, Milton Packer, Akshay S. Desai, Jim Gong, Martin P. Lefkowitz, Adel R. Rizkala, Jean Rouleau, Victor C. Shi, Scott D. Solomon, Karl Swedberg, Michael R. Zile, "Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact", EUROPEAN JOURNAL OF HEART FAILURE, ELSEVIER, AMSTERDAM, NL, NL , (20130901), vol. 15, no. 9, doi:10.1093/eurjhf/hft052, ISSN 1388-9842, pages 1062 - 1073, XP055161544
OPPOSITION- Yancy Clyde W., Jessup Mariell, Bozkurt Biykem, Butler Javed, Casey Donald E., Drazner Mark H., Fonarow Gregg C., Geraci Stephen A., Horwich Tamara, Januzzi James L., Johnson Maryl R., Kasper Edward K., Levy Wayne C., Masoudi Frederick A., Mcbride Patrick E., Mcmurray John J.V., Mitchell Judith E., Peterson Pamela N., Riegel Barbara, Sam Flora, Stevenson Lynne W., Tang W.H. Wilson, Tsai Emily J., Wilkoff Bruce L., "2013 ACCF/AHA Guideline for the Management of Heart Failure : A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines", Circulation, US , (20131015), vol. 128, no. 16, doi:10.1161/CIR.0b013e31829e8776, ISSN 0009-7322, pages e240 - e327, XP055889103
OPPOSITION- Hunt Sharon Ann, Abraham William T., Chin Marshall H., Feldman Arthur M., Francis Gary S., Ganiats Theodore G., Jessup Mariell, Konstam Marvin A., Mancini Donna M., Michl Keith, Oates John A., Rahko Peter S., Silver Marc A., Stevenson Lynne Warner, Yancy Clyde W., "2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults : A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation", Circulation, US , (20090414), vol. 119, no. 14, doi:10.1161/CIRCULATIONAHA.109.192065, ISSN 0009-7322, pages e391 - e479, XP055889096
OPPOSITION- Gu J, Noe A, Chandra P, Al-Fayoumi S, Ligueros-Saylan M, Sarangapani R, Maahs S, Ksander G, Rigel D F, Jeng A Y, Lin T H, Zheng W, Dole W P, "Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).", Journal of clinical pharmacology, Wiley-Blackwell Publishing, Inc., US, US , (20100401), vol. 50, no. 4, doi:10.1177/0091270009343932, ISSN 1552-4604, pages 401 - 414, XP002718352
OPPOSITION- GU J. NOE, CHANDRA et al., "Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi", J. Clin. Pharmacol., (20100000), vol. 50, doi:10.1177/0091270009343932, pages 401 - 14, XP002718352
OPPOSITION- JESSIE GU et al., "Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual-Acting Angiotensin Receptor-Neprilysin Inhibitor (ARNi", Journal of Clinical Pharmacology, (20100000), vol. 50, doi:10.1177/0091270009343932, pages 401 - 414, XP002718352
OPPOSITION- LEFKOWITZ, MARTIN P. et al., "LCZ696, an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure and hypertension", BMC Pharmacology, (20110000), vol. 11, doi:10.1186/1471-2210-11-S1-O3, XP021104814
OPPOSITION- Martin P Lefkowitz, "LCZ696, an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure and hypertension", BMC PHARMACOLOGY, BIOMED CENTRAL, LONDON, GB, GB , (20110801), vol. 11, no. Suppl 1, doi:10.1186/1471-2210-11-S1-O3, ISSN 1471-2210, page O3, XP021104814
OPPOSITION- Chrysant, Steven G., "LCZ-696: angiotensin AT, receptor antagonist/neprilysin inhibitor treatment of heart failure treatment of hypertension", Drugs of the Future, ES , (20110301), vol. 36, no. 3, doi:10.1358/dof.2011.36.3.1588061, ISSN 0377-8282, pages 183 - 190, XP009173432

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents